NEA Management Company’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

NEA Management Company’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-37,093	Closed	-$297K	–	63
2021 Q3	$297K	Hold	37,093	–	–	﹤0.01%	63
2021 Q2	$421K	Hold	37,093	–	–	0.01%	63
2021 Q1	$343K	Hold	37,093	–	–	0.01%	58
2020 Q4	$258K	Hold	37,093	–	–	0.01%	57
2020 Q3	$162K	Sell	37,093 -1	-0%	-$9	0.01%	54
2020 Q2	$342K	Hold	37,094	–	–	0.01%	46
2020 Q1	$539K	Hold	37,094	–	–	0.03%	49
2019 Q4	$438K	Hold	37,094	–	–	0.02%	46
2019 Q3	$935K	Hold	37,094	–	–	0.08%	43
2019 Q2	$943K	Hold	37,094	–	–	0.07%	41
2019 Q1	$1.58M	Hold	37,094	–	–	0.08%	43
2018 Q4	$539K	Hold	37,094	–	–	0.02%	46
2018 Q3	$2.6M	Hold	37,094	–	–	0.11%	42
2018 Q2	$2.75M	Hold	37,094	–	–	0.13%	40
2018 Q1	$3.53M	Hold	37,094	–	–	0.16%	41
2017 Q4	$4.79M	Hold	37,094	–	–	0.2%	37
2017 Q3	$2.52M	Hold	37,094	–	–	0.09%	38
2017 Q2	$3.5M	Hold	37,094	–	–	0.13%	37
2017 Q1	$5.32M	Hold	37,094	–	–	0.19%	29
2016 Q4	$4.7M	Hold	37,094	–	–	0.19%	28
2016 Q3	$5.67M	Hold	37,094	–	–	0.25%	26
2016 Q2	$4.28M	Hold	37,094	–	–	0.22%	30
2016 Q1	$4.21M	Hold	37,094	–	–	0.28%	30
2015 Q4	$7.01M	Buy	37,094 +10,000	+37%	+$1.87M	0.45%	21
2015 Q3	$4.61M	Buy	27,094 +4,907	+22%	+$1.77M	0.3%	31
2015 Q2	$14M	Hold	22,187	–	–	0.73%	21
2015 Q1	$11.4M	Hold	22,187	–	–	0.52%	27
2014 Q4	$11.9M	Hold	22,187	–	–	0.58%	27
2014 Q3	$33.3M	Sell	22,187 -4,654	-17%	-$6.74M	1.69%	15
2014 Q2	$36.8M	Hold	26,841	–	–	1.72%	15
2014 Q1	$37.3M	Hold	26,841	–	–	1.83%	12
2013 Q4	$26.7M	Hold	26,841	–	–	1.29%	12
2013 Q3	$28M	Hold	26,841	–	–	1.11%	14
2013 Q2	$29.3M	Buy	+26,841	New	+$29.9M	1.31%	14

Other funds holding VIRX

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NEA Management Company's VIRX Position: Q4 2021 in Review

NEA Management Company sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 37,093 shares — an estimated $297K sold.

NEA Management Company first reported a position in VIRX in Q2 2013 and held it in 34 quarters. The position peaked at $37.3M in Q1 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

NEA Management Company reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
NEA Management Company sold 37,093 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $297K.
NEA Management Company first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 34 quarters.
NEA Management Company's Viracta Therapeutics, Inc. Common Stock position peaked at $37.3M in Q1 2014.
69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on NEA Management Company's 13F filing for Q4 2021, filed 14 Feb 2022.